The trademark application LEYTEVU was filed by Amgen Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on March 15, 2023, and it was registered by office on June 22, 2023 without any oppositions.
The application was filed in English (French was selected as the second language).
Change of name and professional address of the trademark registration was recorded on November 5, 2023.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations
Pharmaceutical preparations and substances for use in the treatment of hematological, immune, autoimmune, inflammatory and respiratory diseases and disorders
Pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders
Pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders
Pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders
Pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system
Pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure.